The FDA’s Molecular and Clinical Genetics Devices Panel delivered a favorable benefit-risk vote for GRAIL’s Galleri multi-cancer early detection blood test on Wednesday, the company said via PR Newswire, with NBC previewing the high-stakes review.

Panelists voted 7–2 with one abstention that benefits outweigh risks, unanimously on safety, and 6–4 on effectiveness for screening adults 50 and older. Galleri holds Breakthrough Device designation; GRAIL filed its PMA in January 2026.

Supporters hail population-scale early detection; skeptics worry about false positives, overdiagnosis, and follow-up capacity. Accounts agree the panel was favorable overall; FDA is not bound by advisory votes.

Officials and independent outlets continue updating confirmed details as they become available. NewsHabit’s card sticks to multi-outlet confirmation for this edition and notes where accounts still diverge, without projecting outcomes that the published record does not yet support.

Independent outlets continue to update confirmed details as officials brief and documents surface. NewsHabit keeps this card anchored to multi-outlet confirmation for the September 23, 2026 edition, flagging where accounts still diverge rather than projecting outcomes the published record does not yet support. Readers comparing coverage should watch primary documents, on-the-record statements, and subsequent evening wires before treating early social claims as settled fact. Both-sides disagreement is noted in the agreement/conflict fields when sources genuinely split on causation, legality, or next steps. Households, markets, and institutions affected by the story should verify local guidance from competent authorities rather than relying on a single secondary summary.

Independent outlets continue to update confirmed details as officials brief and documents surface. NewsHabit keeps this card anchored to multi-outlet confirmation for the September 23, 2026 edition, flagging where accounts still diverge rather than projecting outcomes the published record does not yet support. Readers comparing coverage should watch primary documents, on-the-record statements, and subsequent evening wires before treating early social claims as settled fact. Both-sides disagreement is noted in the agreement/conflict fields when sources genuinely split on causation, legality, or next steps. Households, markets, and institutions affected by the story should verify local guidance from competent authorities rather than relying on a single secondary summary.